Cas:322725-63-3 Ethyl 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate manufacturer & supplier

Chemical Name:Ethyl 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate

CAS.NO:322725-63-3

Synonyms:6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid ethyl ester

Molecular Formula:C₁₅H₁₆FNO₂

Molecular Weight:261.29100

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:42.09000

Exact Mass:261.11700

LogP:2.97500

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid ethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid ethyl ester Use and application,6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid ethyl ester technical grade,usp/ep/jp grade.

Related News: Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. Ethyl 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate manufacturer The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China. Ethyl 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate supplier There’s still hope for this approach to treating Alzheimer’s disease despite the somewhat mixed results from this trial, said Rebecca Edelmayer, senior director of scientific engagement at the Alzheimer’s Association. Ethyl 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate vendor Complete the research and development of APIs and intermediates, design new patented process routes, and explore new crystal forms. Ethyl 6-fluoro-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylate factory Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms.